Saltar al contenido
Merck

Post-filler vascular occlusion: a cautionary tale and emphasis for early intervention.

Journal of drugs in dermatology : JDD (2013-10-03)
Lindsay K McGuire, Elizabeth K Hale, Loyd S Godwin
RESUMEN

We report a case of a 36-year-old female who experienced significant vascular occlusion after injection with hyaluronic acid into the nasolabial folds. The patient experienced immediate pain after the injection, however, the vascular compromise was not diagnosed and treated until 48 hours later. The patient suffered tissue damage despite treatment with hyaluronidase, hyperbaric oxygen, nitropaste, and aspirin. The case highlights the importance of proper injection technique by a qualified physician, as well as the need for immediate recognition and treatment of vascular occlusion should it occur.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Hialuronidasa from bovine testes, Type I-S, lyophilized powder, 400-1000 units/mg solid
Sigma-Aldrich
Hialuronidasa from bovine testes, Type IV-S, lyophilized powder (essentially salt-free), 750-3000 units/mg solid
Sigma-Aldrich
Hialuronidasa from bovine testes, Type IV-S, powder, suitable for mouse embryo cell culture, 750-3000 units/mg solid
Sigma-Aldrich
Hyaluronidase from sheep testes, Type V, lyophilized powder, ≥1,500 units/mg solid
Sigma-Aldrich
Hialuronidasa from bovine testes, Type VIII, lyophilized powder, 300-1,000 U/mg
Sigma-Aldrich
Hyaluronidase from sheep testes, Type II, lyophilized powder, ≥300 units/mg solid
Sigma-Aldrich
Hialuronidasa from bovine testes, Type VI-S, lyophilized powder, 3,000-15,000 units/mg solid